Precision Genomic Profiling Reveals Multiple Molecular Diagnoses in Gaucher Disease Patients with Atypical Presentations
Key Insights
Researchers at Yale Gaucher Disease Center (search) identified multiple molecular diagnoses in approximately 6% of Gaucher disease (search) patients who presented with atypical clinical features beyond the expected GBA1 (search) genotype-phenotype correlations.
Whole-exome sequencing revealed concurrent genetic conditions including familial Mediterranean fever (search), iron overload (search) disorders, autosomal dominant polycystic kidney disease (search), and constitutional mismatch repair deficiency syndrome in 17 patients with expanded phenotypes.
The study demonstrates how precision medicine approaches combining deep phenotyping, longitudinal follow-up, and genomic analysis can refine diagnoses and optimize therapeutic strategies for rare monogenic disorders.
Gaucher disease (search), despite being a monogenic lysosomal storage disorder, exhibits remarkable phenotypic heterogeneity that cannot be fully explained by GBA1 (search) genotype alone. New research from the Yale Gaucher Disease Center (search) demonstrates how precision genomic profiling can uncover multiple molecular diagnoses in patients with atypical presentations, fundamentally changing our understanding of disease complexity and therapeutic management.
Expanding Beyond Single-Gene Disease Models
The study, published in Frontiers in Genetics, examined 17 patients from a cohort of 275 Gaucher disease (search) patients who exhibited clinical features that deviated from classical presentations. Using whole-exome sequencing and deep phenotyping approaches, researchers identified concurrent genetic conditions in approximately 6% of patients, supporting growing recognition that multi-locus inheritance and blended phenotypes occur in up to 5% of individuals undergoing genomic evaluation.
"While GD is a monogenic disorder, this variability suggests that additional factors, including genetic, epigenetic, or environmental modifiers, may play significant roles in shaping the clinical manifestations of the disease," the researchers noted. The identified cases fell into six broad categories: inflammatory symptoms due to concurrent familial Mediterranean fever (search), complex myopathy presentations, rare genetic diseases, autosomal dominant polycystic kidney disease (search), myoclonic epilepsy (search), and hyperferritinemia with iron overload (search).
Familial Mediterranean Fever Co-occurrence
Four patients presented with unusual inflammatory symptoms that were ultimately attributed to concurrent familial Mediterranean fever (search) (FMF). One 42-year-old patient experienced recurrent severe pericarditis despite standard colchicine therapy and enzyme replacement therapy with imiglucerase. The episodes continued for over two decades until he transitioned to eliglustat substrate reduction therapy, which resulted in sustained remission of pericarditis for six years.
Whole-exome sequencing revealed heterozygous variants in the MEFV (search) gene in these patients. The co-occurrence of Gaucher disease (search) and FMF in individuals of Ashkenazi Jewish descent is particularly striking, given the high carrier frequency of both GBA1 (search) and MEFV variants in this population. Historical genomic data from medieval Ashkenazi Jewish individuals have identified the presence of both variants, suggesting a possible shared evolutionary background.
Iron Metabolism Disorders
Five patients exhibited hyperferritinemia with elevated iron saturation and definitive evidence of iron overload (search) on imaging, an uncommon finding in Gaucher disease (search). One patient presented with splenomegaly, thrombocytopenia, and elevated ferritin at age 20. Liver biopsy revealed both Gaucher cells and hepatocyte siderosis, and MRI demonstrated iron overload in liver and bone marrow.
Genetic analysis revealed variants in iron metabolism genes, including homozygous p.His63Asp variants in the HFE (search) gene and polymorphisms in the SLC40A1 (search) gene encoding ferroportin. These findings point to potential dysregulation of macrophage iron handling, possibly involving ferroportin-hepcidin signaling pathways not typically seen in isolated Gaucher disease (search).
Complex Genetic Interactions
The study identified several cases of rare concurrent conditions, including two siblings with Gaucher disease (search) who developed T-cell acute lymphoblastic lymphoma (search) at young ages. Exome analysis revealed homozygous variants in the MSH6 (search) mismatch repair gene, indicating constitutional mismatch repair deficiency syndrome. Another patient was diagnosed with both Gaucher disease and metachromatic leukodystrophy (search), representing two distinct lysosomal storage disorders.
Cardiovascular manifestations, typically uncommon in type 1 Gaucher disease (search), were observed in two patients with additional pathogenic variants in genes linked to fibromuscular dysplasia (search) and Brugada syndrome (search). These findings highlight the importance of comprehensive genomic evaluation when clinical presentations deviate from expected patterns.
Early Treatment Outcomes in Pediatric Patients
Complementary research on enzyme replacement therapy in very young children provides crucial insights into early intervention strategies. A study of 11 infants and children under 4 years old treated with velaglucerase alfa demonstrated positive clinical outcomes with no drug-related adverse events.
The majority of patients achieved normalization of spleen and liver sizes after 6 months of treatment. Biomarker levels, including glucosylsphingosine (Lyso-Gb1), showed rapid decreases within 6 months of therapy initiation. Lyso-Gb1 levels decreased from presentation values of 90-874 ng/mL to clinically acceptable values of 4-26 ng/mL at latest measurement.
Treatment patterns varied based on disease severity, with eight patients receiving weekly infusions rather than the standard every-other-week schedule. The frequent dosing schedule was associated with rapid biomarker improvement and positive parental attitudes toward treatment compliance.
Precision Medicine Framework
The research establishes a practical framework for implementing precision medicine in Gaucher disease (search) through three essential pillars: integrated clinical assessment combining longitudinal deep phenotyping with family history analysis; genomic integration using whole-exome sequencing to uncover variants explaining atypical features; and therapeutic individualization adapting treatment based on concurrent genetic conditions.
This approach proved particularly valuable when clinical features deviated from expected trajectories based on GBA1 (search) genotype or age at onset. For example, while hyperferritinemia is common in Gaucher disease (search), true iron overload (search) with elevated iron saturation and hepatic iron deposition warranted investigation for concurrent iron metabolism disorders.
Clinical Implications and Future Directions
The convergence of Gaucher disease (search) with other genetic conditions raises important questions about shared biological pathways. In patients with concurrent FMF, both disorders involve inflammasome activation, which may synergistically amplify systemic inflammation and upregulate glucosylceramide synthesis. This could explain the enhanced clinical response observed with glucosylceramide synthase inhibitors like eliglustat compared to enzyme replacement therapy.
The findings suggest that standard Gaucher disease (search) therapies, especially substrate reduction therapy, may exert ancillary benefits on coexisting genetic disorders through shared biological pathways. As genomic technologies become increasingly accessible, this framework offers a path forward for individualized care and provides a model for applying precision medicine across the broader landscape of rare diseases.
The research demonstrates that approximately 6% of Gaucher disease (search) patients may benefit from expanded genomic evaluation when presenting with atypical features, fundamentally changing diagnostic and therapeutic approaches for this complex lysosomal storage disorder.